Celiac.com Sponsor (A1):



Celiac.com Sponsor (A1-m):


  • You've found your Celiac Tribe! Join our like-minded, private community and share your story, get encouragement and connect with others.

    💬

    • Sign In
    • Sign Up
  • Jefferson Adams

    Splenic Volume Differs in Complicated vs. Non-complicated Celiac Disease

    Jefferson Adams
    0
    Reviewed and edited by a celiac disease expert.

      Splenic volume is the key difference between complicated and non-complicated celiac disease.


    Photo: CC--Susan
    Caption: Photo: CC--Susan

    Celiac.com 11/17/2016 - Studies in small groups of patients indicated that splenic volume may be decreased in patients with celiac disease, refractory celiac disease (RCD) type II and enteropathy-associated T-cell lymphoma (EATL).

    A team of researchers recently set out to assess splenic volume in a large group of uncomplicated celiac disease, RCD II and EATL patients and in healthy controls. The research team included Tom van Gils, Petula Nijeboer, Jan Hein TM van Waesberghe, Veerle MH Coupé, Kiki Janssen, Jessy A Zegers, Shaikh A. Nurmohamed, Georg Kraal, Sabine CI Jiskoot, Gerd Bouma, Chris JJ Mulder. They are variously affiliated with the Celiac Center Amsterdam, Department of Gastroenterology and Hepatology, the Department of Radiology, the Department of Epidemiology and Biostatistics, the Department of Nephrology, the Department of Molecular Cell Biology and Immunology at VU University Medical Center, Amsterdam, The Netherlands, and with the Department of Radiology, St Jansdal, Harderwijk, The Netherlands.



    Celiac.com Sponsor (A12):






    Celiac.com Sponsor (A12-m):




    For their retrospective cohort they included 77 patients with uncomplicated celiac disease (of whom 39 in remission), 29 patients with RCD II, 24 patients with EATL, and 12 patients with both RCD II and EATL. The control group included 149 healthy living kidney donors. The team used computed tomography to determine splenic volume.

    The median splenic volume in the uncomplicated celiac disease group was significantly larger than in controls (202 cm3 (interquartile range (IQR): 154–275) versus 183 cm3 (IQR: 140–232), p = 0.02). After correction for body surface area, age and gender, the ratio of splenic volume in uncomplicated celiac disease versus controls was 1.28 (95% confidence interval: 1.20–1.36; p less than 0.001).

    On average, RCD II patients showed smaller splenic volume (118 cm3 (IQR 83–181)) than the median splenic volume in the control group (p less than 0.001).

    These results show wide variation in splenic volume among patients. In uncomplicated celiac disease, splenic volume is typically enlarged. Lower splenic volume in RCD II patients may be clinically relevant, given the the compromised immune conditions of these patients.

    Source:

    0

    User Feedback

    Recommended Comments

    There are no comments to display.



    Join the conversation

    You are posting as a guest. If you have an account, sign in now to post with your account.
    Note: Your post will require moderator approval before it will be visible.

    Guest
    Add a comment...

    ×   Pasted as rich text.   Restore formatting

      Only 75 emoji are allowed.

    ×   Your link has been automatically embedded.   Display as a link instead

    ×   Your previous content has been restored.   Clear editor

    ×   You cannot paste images directly. Upload or insert images from URL.


  • About Me

    Jefferson Adams is Celiac.com's senior writer and Digital Content Director. He earned his B.A. and M.F.A. at Arizona State University, and has authored more than 2,500 articles on celiac disease. His coursework includes studies in science, scientific methodology, biology, anatomy, medicine, logic, and advanced research. He previously served as SF Health News Examiner for Examiner.com, and devised health and medical content for Sharecare.com. Jefferson has spoken about celiac disease to the media, including an appearance on the KQED radio show Forum, and is the editor of the book "Cereal Killers" by Scott Adams and Ron Hoggan, Ed.D.


  • Celiac.com Sponsor (A17):
    Celiac.com Sponsor (A17):





    Celiac.com Sponsors (A17-m):




  • Related Articles

    Jefferson Adams
    Celiac.com 05/24/2016 - People with type II refractory celiac disease (RCD), suffer from severe malabsorption syndrome and face a poor prognosis, as there is currently no effective treatment.
    Prompted by the regenerative and immune-influencing properties of mesenchymal stem cells (MSCs), a research team recently set out to assess the viability, safety, and efficacy of a series of infusions of autologous bone marrow-derived MSCs in a 51-year-old woman with type II RCD.
    The research team included R Ciccocioppo, A Gallia, MA Avanzini, E Betti, C Picone, A Vanoli, C Paganini, F Biagi, R Maccario, and GR Corazza. They are variously affiliated with the...

    Jefferson Adams
    Celiac.com 07/11/2016 - Collagenous sprue is a rare form of small bowel enteropathy characterized by a thickened basement membrane and is considered to be directly related to celiac disease.
    Doctors have numerous treatment strategies for celiac sprue, but there is currently no effective standardized therapy. One medical team recently described four cases of celiac sprue and proposes thioguanine (6-TG) treatment, based on their results.
    The research team included Tom van Gils, Tine van de Donk, Gerd Bouma, Foke van Delft, E Andra Neefjes-Borst, and Chris JJ Mulder. They are variously affiliated with the Department of Gastroenterology and Hepatology...

    Jefferson Adams
    Celiac.com 10/17/2016 - Refractory celiac disease is a severe condition with few good treatment options, and which often eventually results in death. A group of researchers recently set out to create a prognostic model to estimate survival of patients with refractory celiac disease.
    The research team included A. Rubio-Tapia, G. Malamut, W. H. M. Verbeek, R. L. J. van Wanrooij, D. A. Leffler, S. I. Niveloni, C. Arguelles-Grande, B. D. Lahr, A. R. Zinsmeister, J. A. Murray, C. P. Kelly, J. C. Bai, P. H. Green, S. Daum, C. J. J. Mulder, and C. Cellier. They are variously affiliated with the Mayo Clinic, Rochester, MN, USA, the Hopital Europeen Georges...

    Jefferson Adams
    Celiac.com 11/03/2016 - Refractory celiac disease type II (RCDII) often transforms into an enteropathy-associated T-cell lymphoma (EATL), a serious condition that requires intensive treatment. Current treatment strategies for RCDII include cladribine(2-CdA) and autologous stem cell transplantation (auSCT).
    A team of researchers recently set out to assess long-term survival in refractory celiac disease type II, and to define clear prognostic criteria for EATL development comparing two treatment strategies. They also wanted to evaluate histological response as prognostic factor. The research team included P Nijeboer, RLJ van Wanrooij, T van Gils, NJ Wierdsma...